EnvisionTEC, Inc.

DUBLIN, Feb. 19, 2024 /PRNewswire/ -- The '3D Cell Cultures: Technologies and Global Markets' report has been added to ResearchAndMarkets.com's offering. 3D cell culture technologies are a powerful tool for studying cell biology, disease mechanisms and drug discovery. 3D cell culture models mimic the 3D structure and cell-cell interactions that are found in real tissues, making them more accurate and predictive than traditional 2D cell culture models. There are a variety of 3D cell culture technologies available, including: Scaffold-based 3D cell culture: This approach uses a scaffold to provide a 3D support structure for cells to grow on. Scaffolds can be made from a variety of materials, including natural polymers, synthetic polymers and hydrogels. Scaffold-free 3D cell culture: This approach does not use a scaffold. Instead, cells are grown in a suspension of culture medium and gel-forming agents, such as collagen or Matrigel. Bioprinting: This approach uses a 3D printer to deposit cells and biomaterials layer-by-layer to create complex 3D cell culture models. 3D cell culture technologies have a wide range of applications, including: Drug discovery: 3D cell culture models can be used to screen new drug candidates for safety and efficacy before they are tested in clinical trials. 3D cell culture models can also be used to study the mechanisms of drug resistance and to develop new strategies to overcome drug resistance. Disease modeling: 3D cell culture models can be used to study the biology of diseases and to develop new treatments. For example, 3D cancer models can be used to study tumor growth and metastasis, and 3D neurodegenerative disease models can be used to study the progression of neurodegenerative diseases. Regenerative medicine: 3D cell culture models can be used to develop new cell-based therapies for a variety of diseases. For example, 3D skin models can be used to grow new skin for patients with burns or other skin injuries, and 3D liver models can be used to grow new liver tissue for patients with liver disease. This report aims to provide a comprehensive study of the global 3D cell culture technologies market. It provides a detailed description of the different types of healthcare interoperability solutions and their current and historical market revenues. The scope of the report encompasses the major types of 3D cell culture which are being used by industry, academic researchers, government labs, and independent research groups. This includes the main inputs such as cell lines, media, sera, reagents, software, and instrumentation. It analyzes the current market status, examines future market drivers and presents forecasts of growth over the next five years. The market structure has been reorganized for this edition. Also, more research was done on base case data for different product areas. The greater emphasis is on the different products used for 3D cell culture, but the report also investigates the market in terms of types of applications, end users and geographic regions. The Report Includes 17 data tables and 105 additional tables An overview of the global market landscape related to the 3D cell cultures technologies In-depth analysis of global market trends, featuring historical revenue data for 2020-2022, estimated figures for 2023, as well as forecasts for 2028. This analysis includes projections of Compound Annual Growth Rates (CAGRs) spanning through 2028 Evaluation of the current market size and revenue growth prospects specific to 3D cell cultures technologies, accompanied by a comprehensive market share analysis categorized by type, end user, and geographical region Information on analytical systems used in tissue and cell culture, cellomics, and human cancer model initiative (HCMI) Details about assay development for mesenchymal stem cells, In Vitro testing of adventitious agents and description of assays and assay kits A look at the main classes of models for researching cancer and other diseases, benefits of 3D models to cancer research and description of 3D engineered scaffolds Analysis of the market's dynamics, specifically growth drivers, restraints, and opportunities and discussion on the impact of COVID-19 on the world of cell culture Insights into U.S. regulatory status of bioprinted products; basic guidance for the regulation of biologics, regenerative medicine and xenotransplants Relevant patent analysis, including recent activity and a list of key patents Detailed profiles of leading market participants, providing a descriptive overview of their respective businesses, including Abcam PLC, Agilent Technologies Inc., Corning Inc., Merck KGAA, Beckman Coulter, and Synvivo Inc. Key Topics Covered: Chapter 1 Introduction Chapter 2 Summary and Highlights Chapter 3 Market Overview Chapter 4 Market, by Type Chapter 5 Assays, Imaging and Analysis Chapter 6 Regulation and Standardization Chapter 7 3D Models for Cancer Chapter 8 Landscape for Toxicology and Drug Safety Testing Chapter 9 Market Breakdown by Region Chapter 10 Stem Cell Landscape Chapter 11 Regenerative Medicine: Organ Transplants and Skin Substitutes Chapter 12 Company Profiles 3D Bioprinting Solutions 3D Biotek 4D Technology Abcam Akron Biotech Agilent Technologies Alpco Amsbio Beckman Coulter Bioinspired Solutions Biotime Biovision Cell Applications Cellink Corning Cyprotex Cytiva Cytoo EMD Millipore / Merck Emulate Envisiontec Epithelix Eurofins Greiner Bio-One International Hamilton Robotics Hub Organoids Hurel Corp. Insphero Invitrocue Kiyatec Inc. Lifenet Health Lorem Vascular / Cytori Therapeutics Mattek Mimetas Organovo Holdings Perkinelmer Plasticell Pluristem Therapeutics Poietis Promega Corp. Seahorse Bioscience Stemcell Technologies Stratatech Corp. Synvivo Tap Biosystems Tecan Trading Zen-Bio For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Future Market Insights, Inc. (FMI) predicts a transformative future for the 3D bioprinting market, fueled by advancements in biomaterials and the rise of personalized medicine. Explore the intricate dynamics of the growing market and discover valuable stakeholder opportunities in our detailed FMI report. NEWARK, Del., Jan. 24, 2024 /PRNewswire/ -- The global 3D Bio-Printing Market is expected to grow at an exponential CAGR of 11.8% between 2024 and 2034, to reach US$ 2.24 billion in 2024 and US$ 6.82 billion by 2034. The desire for customized medicine, growing investments in bio printing technology, partnerships between biotech firms, healthcare providers, and research institutes, as well as advancements in tissue engineering and regenerative medicine, are driving the growth of the worldwide 3D bio-printing demand. Request Exclusive Sample Report: 3D Bio-Printing Industry Strategic Insights, The field of 3D printing has witnessed a continuous improvement in biocompatible materials, particularly biomimetic materials, designed to mimic natural tissues' properties, such as their elasticity and strength. This development has significantly enhanced the accuracy and functionality of 3D printed structures, making them more suitable for biomedical applications. The growing demand for 3D bio-printing is a significant trend driven by the need for personalized medicine. This approach involves creating customized tissues and organs tailored to patients' needs. This is achieved by using a patient's cells to create 3D-printed structures, which minimizes the risk of rejection and improves their overall effectiveness. The potential benefits of 3D bio-printing are enormous, as it could revolutionize regenerative medicine, providing a new way to treat diseases and injuries that were previously untreatable. The ability to construct operational tissues and organs compatible with the human body opens up new possibilities for transplants and other medical procedures, improving the quality of life for patients worldwide. "3D bio-printing technology is being used by healthcare businesses more and more for medication research, which lowers costs, speeds up testing, and minimizes animal use. Sales of this technology are anticipated to rise due to positive regulatory enforcement. Nonetheless, the market demands a highly trained labor pool and substantial development costs. Furthermore, 3D bio printing might become laborious due to continuous process control." Says Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.). Key Takeaways from the 3D Bio-Printing Market The United States 3D bio-printing industry is projected to experience a CAGR of 14.1% through 2034. Germany's 3D bio-printing demand is expected to demonstrate a rapid CAGR of 14.9% through 2034. Chinese 3D bio-printing industry is anticipated to see a promising CAGR of 13.9% through 2034. Japan's market for 3D bio-printing showcases a moderate CAGR of 12.6% through 2034. Russian 3D bio-printing market is expected to display a modest CAGR of 10.0% through 2034. Competitive Landscape of the 3D Bio-Printing Market Companies in the global 3D bio-printing sector are determining the market's future by continuously innovating, collaborating strategically, and increasing applications. Leading companies invest extensively in research and development to expand bio-printing technology, resulting in more complex and functioning tissues for medical applications. Collaborations with academic institutes and healthcare organizations promote a multidisciplinary approach, hastening the translation of 3D bio-printing into therapeutic applications. Market players are always exploring new materials to enhance the biocompatibility and structural integrity of printed tissues, such as bio-inks and biomimetic compounds. Strategic partnerships, legal compliance, and market expansion efforts all contribute to the industry's evolution and help shape a future in which 3D bio printing is widely used for organ transplantation, regenerative medicine, and customized medicine. Key Companies in the 3D Bio-Printing Market 3D Bioprinting Solutions GE Healthcare Inventia Life Science PTY LTD Optomec Inc. Organovo Holdings Inc Pandorum Technologies pvt. Ltd. Poietis Precise Bio Regenovo Biotechnology Co. Ltd. Renishaw plc. Revotek co., ltd. Rokit Healthcare, inc. Stratasys Ltd.Vivax Bio, LLC Advanced Solutions Life Sciences, LLC Allevi Inc. Aspect Biosystems Ltd. Bico group ab Bio3D Technologies Pte. Ltd. Cellink Global Collplant Biotechnologies Ltd. Cyfuse Biomedical K.K. Electro Optical Systems EnvisionTEC, Inc. Foldink Life Science Technologies Formlabs, Inc. Purchase this report now to get key companies with their Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis. Recent Developments in the 3D Bio-Printing Market Researchers from the Beijing Institute of Technology, Pusan National University, and Pohang University utilized 3D bio-printing in January 2024 to study the brain's blood artery layout and its impact on tumor cell activity. A leading company in creating human tissue that is similar to the natural world for medical treatment, FluidForm Bio, will present new developments in creating human heart tissues using FRESH 3D bio-printing in January 2024. Key Segments covered in 3D Bio Printing Industry Report: By Technology: Stereolithography Selective Laser Sintering Electron Beam Melting Fused Deposition Modeling Laminated Object Manufacturing Inkjet Printing Multi-phase Jet Solidification By Application: Surgical Simulation and Training Models Prosthetic Devices Tissue Engineering and Regenerative Medicine Orthopedic Implants Dental Implants Medical Sensors Others By Region North America Latin America Europe East Asia South Asia Oceania Middle East and Africa Request to Access the Detail Research Methodology from here! About the Author: Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher. Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation. Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News. Explore FMI's Extensive Coverage in the Healthcare Domain: 3D Printed Hip And Knee Implants Market Covering Sales Outlook, Up-to-date Key Trends, Market Size and Forecast, 2023-2033. – Review and Request to Access the Sample PDF. 3D Printed Medical Devices Market Covering Sales Outlook, Up-to-date Key Trends, Market Size and Forecast, 2023-2033. - Review and Request to Access the Sample PDF. Infection Prevention Market Forecast by Consumables and Disinfectors Products from 2024 to 2034. - Review and Request to Access the Sample PDF. Intraoral Scanner Market Forecast by Open System and Closed System Modality for 2024 to 2034. - Review and Request to Access the Sample PDF. Femtech Market Forecast by Consumer Products and Diagnostics Product Type from 2024 to 2034. - Review and Request to Access the Sample PDF. About Future Market Insights (FMI) Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI's latest market research reports and market analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers. Contact Us Nandini Singh Sawlani Future Market Insights Inc. Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, USA T: +1-845-579-5705 For Sales Enquiries: [email protected] Website: LinkedIn| Twitter| Blogs | YouTube Logo: SOURCE Future Market Insights

DUBLIN, Jan. 4, 2023 /PRNewswire/ -- The "Bioprinting: Markets and Opportunities" report has been added to ResearchAndMarkets.com's offering. Revenues from bioprinting are expected to reach almost $1.2 billion in 2028, compared with just $182 million today The new report provides a realistic assessment of bioprinting's commercial future including an analysis of how the major bioprinting companies are designing their marketing strategies. In addition to the pure play bioprinting companies, the bioprinting sector is seeing involvement from major life science companies and 3D printing companies. By 2028, the analyst expects almost 70 percent of the bioprinting industry to come from applications and service revenues. The new report claims that we are many years from transplanting printed organs. Nonetheless, bioprinting is finding a rapidly growing application in drug and cosmetics testing. Using printed tissues and organs avoids the need for animal testing and enables testing on printed tissue and organs that are realistic substitutes for the real thing. Report Scope: The analyst has been tracking the bioprinting industry for almost a decade and this is its third major bioprinting report. The report covers bioinks and bio-printing related applications, as well as the bioprinters themselves. Applications discussed in the report include drug discovery and testing, cosmetics testing, tissue and bone printing. We also examine the long-term prospects for transplanting bioprinted organs. And there is a chapter on new directions for bioprinting including discussions on soft robotics, pill printing, and printed food. There are now well over 100 firms in the bioprinting sector, but most of these companies have negligible revenues. Among the firms that are discussed in this report are 3DBio Therapeutics, 3D Systems/Systemic Bio, BICO (Cellink), Collplant, Cyfuse, EnvisionTEC/Desktop Metal, FluidForm, Inventia Life Science, Organovo Holdings, Poietis, Regamat, Rokit Healthcare and many others. According to Lawrence Gasman, author of the report, "New applications are quickly emerging for bioprinting, and they are very much in line with important megatrends in healthcare - notably the trends towards personalized medicine and bringing care closer to the patient. For example, bioprinting can enable procedures such as skin grafting to be performed in a clinic rather than at specialized hospitals." Report Highlights Production-grade bioprinters and reproducible bioprinting applications are coming to the fore. By 2031, R&D service revenues will clock up almost $250 million in service/applications revenue for bioprinting, but this will still only amount to 12 percent of total service/applications revenues in the bioprinting industry. The analyst expects technological innovation across the entire bioprinting sector to accelerate. The new report points to three developments in particular as areas of strong commercial potential. One of these is the arrival of organs-on-a-chip, a product class that bioprinting does much to enable. The report also predicts that bioprinters will move beyond the currently dominant extrusion and inkjet machines. Already as many as 20 novel ways of doing bioprinting are emerging from leading labs and healthcare facilities worldwide. While extrusion and inkjet bioprinters will account for well over 90 percent of bioprinter revenues in 2022, but by 2031, 15 percent of bioprinter revenues will come from printers based on entirely novel printing technologies. Another technical trend that is leading bioprinting forward technologically and will improve costs to patients and expand capabilities is the trend toward next-generation bioprinting platforms that have greater capacities, automate much of the work, and integrate medical functionality well beyond basic bioprinting. By 2031 the analyst expects production grade bioprinters or biomanufacturing platforms incorporating bioprinting to clock up around $100 million in revenues. Key Topics Covered: Chapter One: Overview 1.1 Background to Report: A Renaissance for Bioprinting? 1.2 Bioprinting: An Attractive Business Opportunity Going Forward 1.2.1 History and Prospects 1.2.2 Bioprinting Industry Structure 1.2.3 Evolution of the Bioprinting Industry 1.3 Geographical Diversity of Companies 1.4 Goal, Scope and Plan of this Report 1.5 Methodology of this Report 1.5.1 Forecasting Methodology and Assumptions 1.6 Key Points from this Chapter Chapter Two: Bioprinting: Market Drivers and Market Challenges 2.1 Factors that Could Lead to the "Bioprinting Moment" 2.2 The COVID Factor: COVID as a Bioprinting Market Driver 2.3 The Aging Population: The Role of Bioprinting 2.4 Bioprinting, Personalized Medicine and Bringing Healthcare Closer to the Patient 2.5 New Technologies Emerge Since the Previous Bioprinting Moment 2.5.1 Challenges to Technological Advances in Bioprinting 2.6 The Growing Potential for Modeling 2.7 Impact of Government Regulation and Funding 2.8 A Broader Range of Bioinks 2.9 Ethical Concerns with Bioprinting 2.10 Key Points from this Chapter Chapter Three: Bioprinters: Technical and Market Evolution 3.1 The Essence of a Bioprinter 3.2 Extrusion Bioprinters 3.2.1 Examples of Extrusion Bioprinters 3.2.2 The Future of Extrusion-based Bioprinting 3.3 Inkjet Bioprinters 3.3.1 Thermal Inkjet for Bioprinting 3.3.2 Piezoelectric Inkjet for Bioprinting 3.3.3 The Rastrum Bioprinter: An Example of an Inkjet Printer 3.4 Stereolithography (SLA) 3.4.1 The Problem with SLA-based Bioprinting 3.4.2 Manufacturers of SLA Bioprinters 3.5 Other Bioprinting Technologies 3.6 Ten-year Forecasts of Bioprinter Markets by Printer Technology and Printer Type 3.6.1 From Research Bioprinting to Biofabrication: A Forecast 3.7 Key Points from this Chapter Chapter Four: Bioinks 4.1 Bioink Introductory 4.1.1 Scaffold-based and Scaffold-free Bioprinting 4.1.2 Hydrogels 4.1.3 Stem Cells and Bioprinting 4.1.4 Spheroids and Organoids 4.1.5 Ceramics and Bioprinting 4.1.6 A Note on Shear Printing 4.2 Types of Bioinks: Functionality 4.2.1 Sacrificial Bioinks 4.2.2 Functional Bioinks 4.2.3 Support Bioinks 4.3 Materials for Bioinks 4.3.1 Agarose 4.3.2 Alginate 4.3.3 Collagen 4.3.4 Gelatin 4.3.5 GelMA 4.3.6 Chitosan 4.3.7 Hyaluronic Acid 4.3.8 dECM 4.3.9 Fibrin 4.3.10 Cellulose 4.3.11 Silk 4.3.12 Extracellular matrix (ECM)-based bioinks 4.3.13 Role of Synthetic Polymers 4.3.14 Smart Bioinks and Bioinks with Advanced Material Additives 4.4 Phasing out Animal Materials 4.5 Bioink Supply Chain and Suppliers 4.6 Key Points from this Chapter Chapter Five: Mainstream Bioprinting Applications 5.1 Bioprinting Applications Analysis: Introductory 5.2 Bioprinting and Improved Medical Modeling 5.2.1 Organs-on-a-chip 5.2.2 Disease Modeling 5.3 Bioprinting Skin 5.3.1 Background to Skin Grafting 5.3.2 Bioprinting and Burn Victims 5.3.3 Bioinks for Skin Bioprinting 5.3.4 Cosmetics Testing 5.4 Bone and Cartilage Printing 5.4.1 Materials for Bone and Cartilage Printing 5.5 Organ Printing and Vascular Printing 5.5.1 Competition Between Printed Organs and Living Organs 5.5.2 Bladder Printing 5.5.3 Bioprinting and Breast Implants 5.5.4 Liver Printing 5.5.5 Endocrine System 5.5.6 A Printed Pancreas 5.5.7 Kidney Bioprinting 5.5.8 Lungs 5.5.9 Ears and Noses 5.5.10 Eyes 5.5.11 Hearts and Vasculature 5.5.12 Bioprinting and Neural Tissue 5.6 A Note on Dental Applications of Bioprinting 5.7 Key Points from this Chapter Chapter Six: New Directions in Bioprinting 6.1 Introduction 6.2 Soft Robotics 6.2.1 Soft Robotics and Printing Using Biological Materials 6.3 Food Printing 6.3.1 Drivers for Food Printing 6.3.2 Food Printers and Food Design 6.3.3 Food Printers Currently Available 6.3.4 Bioprinting Meat 6.3.5 Printing Candies and Chocolates 6.3.6 3D Printing-Themed Restaurants 6.4. Pill Printing 6.4.1 Manufacturing of Pills Using 3D Printing: Advantages and Disadvantages 6.4.2 Structure of a Growing Industry 6.5 A Note on Medical Devices 6.6 Key Points from this Report Chapter Seven: Profiles of Nine Leading Bioprinting Firms and Their Strategies 7.1 Criteria for Profiling 7.2 3DBio Therapeutics: Full Bioprinting Package for Healthcare Providers 7.3 3D Systems/Systemic Bio: Still Feeling its Way in the Bioprinting Business? 7.4 BICO (Cellink): Bioconvergence Conglomerate 7.5 Cyfuse - Japanese Bioprinting Firm 7.6 EnvisionTEC/Desktop Metal: More Interest in Bioprinting 7.7 FluidForm - Building Ties to Important Companies with Cutting Edge Technology 7.8 Inventia Life Science: Breaking Out from R&D 7.9 Organovo Holdings: More Focus Than Before 7.10 Rokit Healthcare - Korean Bioprinting and Google Cloud About the Analyst For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets